Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 3, 2006, Pages 488-495

  Chen, Frank C ^a   Ogut, Ozgur ^a   Rhee, Albert Y ^b   Hoit, Brian D ^c   Brozovich, Frank V ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibition; Congestive heart failure; Flow mediated vasodilatation; Myosin phosphatase; Nitric oxide; Vascular reactivity; Vasodilatation

Indexed keywords

CAPTOPRIL; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; ISOENZYME; LEUCINE ZIPPER PROTEIN; MYOSIN LIGHT CHAIN PHOSPHATASE; PRAZOSIN; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEART AFTERLOAD; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; ILIAC ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE RELAXATION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FAILURE, CONGESTIVE; MALE; MYOSIN-LIGHT-CHAIN PHOSPHATASE; MYOSINS; NITRIC OXIDE; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

ANIMALIA;

EID: 33748437056     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.05.018     Document Type: Article

References (47)

1. Kubo S.H., Rector T.S., Bank A.J., Williams R.E., and Heifetz S.M. Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation 84 (1991) 1589-1596
2. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
3. Konstam M.A. Improving clinical outcomes with drug treatment in heart failure: what have trials taught?. Am J Cardiol 91 (2003) 9-14
4. Dzau V.J. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
5. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
6. Zalba G., San Jose G., Moreno M.U., Fortuno M.A., Fortuno A., Beaumont F.J., et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 38 (2001) 1395-1399
7. Li P.F., Dietz R., and von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96 (1997) 3602-3609
8. Zafari A.M., Ushio-Fukai M., Akers M., Yin Q., Shah A., Harrison D.G., et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 32 (1998) 488-495
9. Katz S.D., Schwarz M., Yuen J., and LeJemtel T.H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 88 (1993) 55-61
10. Kaiser L., Spickard R.C., and Olivier N.B. Heart failure depresses endothelium dependent responses in canine femoral artery. Am J Physiol 256 (1989) H962-H967
11. Karim S.M., Rhee A.Y., Given A.M., Faulx M.D., Hoit B.D., and Brozovich F.V. Vascular reactivity in heart failure: role of myosin light chain phosphatase. Circ Res 95 (2004) 612-618
12. Abassi Z.A., Gurbanov K., Mulroney S.E., Potlog C., Opgenorth T.J., Hoffman A., et al. Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II. Circulation 96 (1997) 3655-3664
13. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83 (2003) 1325-1358
14. Surks H.K., Mochizuki N., Kasai Y., Georgescu S.P., Tang K.M., Ito M., et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Iα. Science 286 (1999) 1583-1587
15. Hartshorne D.J., Ito M., and Erdodi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil 19 (1998) 325-341
16. Lincoln T.M., Dey N., and Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 91 (2001) 1421-1430
17. Furchgott R.F. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 19 (1999) 235-251
18. Khatri J.J., Joyce K.M., Brozovich F.V., and Fisher S.A. Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem 276 (2001) 37250-37257
19. Huang Q.Q., Fisher S.A., and Brozovich F.V. Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem 279 (2004) 597-603
20. Delp M.D., Duan C., Mattson J.P., and Musch T.I. Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure. J Appl Physiol 83 (1997) 1291-1299
21. Selye H., Bajusz E., Grasso S., and Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11 (1960) 398-407
22. Pfeffer J.M., Pfeffer M.A., and Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57 (1985) 84-95
23. 2+ handling observed in the mesenteric arterial tree of spontaneously hypertensive rats. J Pharmacol Exp Ther 313 (2005) 359-367
24. Morgan E.E., Faulx M.D., McElfresh T.A., Kung T.A., Zawaneh M.S., Stanley W.C., et al. Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol 287 (2004) H2049-H2053
25. Awan N.A., Miller R.R., DeMaria A.N., Maxwell K.S., Neumann A., and Mason D.T. Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography. Circulation 56 (1977) 346-354
26. Miller R.R., Awan N.A., Maxwell K.S., and Mason D.T. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med 297 (1977) 303-307
27. Wooldridge A.A., MacDonald J.A., Erdodi F., Ma C., Borman M.A., Hartshorne D.J., et al. Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J Biol Chem 279 (2004) 34496-34504
28. Nickenig G., and Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105 (2002) 393-396
29. Nickenig G., and Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II. AT(1) receptor regulation. Circulation 105 (2002) 530-536
30. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
31. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
32. Yusuf S., Pepine C.J., Garces C., Pouleur H., Salem D., Kostis J., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340 (1992) 1173-1178
33. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
34. Dirksen W.P., Vladic F., and Fisher S.A. A myosin phosphatase targeting subunit isoform transition defines a smooth muscle developmental phenotypic switch. Am J Physiol 278 (2000) C589-C600
35. Pfeffer J.M., Pfeffer M.A., and Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 75 (1987) 149-155
36. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
37. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., and Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
38. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
39. Hunter I., Cobban H.J., Vandenabeele P., MacEwan D.J., and Nixon G.F. Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: role in the Ca2+ sensitization of myosin light chain20 phosphorylation. Mol Pharmacol 63 (2003) 714-721
40. Parris J.R., Cobban H.J., Littlejohn A.F., MacEwan D.J., and Nixon G.F. Tumour necrosis factor-alpha activates a calcium sensitization pathway in guinea-pig bronchial smooth muscle. J Physiol 518 (1999) 561-569
41. Kandabashi T., Shimokawa H., Miyata K., Kunihiro I., Kawano Y., Fukata Y., et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 101 (2000) 1319-1323
42. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
43. Isabelle M., Monteil C., Moritz F., Dautreaux B., Henry J.P., Richard V., et al. Role of alpha1-adrenoreceptors in cocaine-induced NADPH oxidase expression and cardiac dysfunction. Cardiovasc Res 67 (2005) 699-704
44. Khaper N., and Singal P.K. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol 29 (1997) 856-861
45. Carson P., Ziesche S., Johnson G., and Cohn J.N. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5 (1999) 178-187
46. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., et al. African-American heart failure trial investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
47. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552